Dabarun Promoter Novel Yana Haɓaka Aminci da Ingantaccen Maganin CAR-T a cikin Cutar sankarar ƙwayar cuta B Cell

Beijing, China - Yuli 23, 2024- A cikin wani ci gaba mai ban sha'awa, asibitin Lu Daopei, tare da haɗin gwiwar Hebei Senlang Biotechnology, sun fitar da sakamako masu ban sha'awa daga sabon binciken da suka yi game da maganin ƙwayoyin cuta na chimeric antigen receptor T (CAR-T). Wannan binciken, wanda ke mayar da hankali kan inganci da amincin ƙwayoyin CAR-T da aka yi amfani da su tare da masu tallata daban-daban, yana nuna babban ci gaba a cikin maganin cutar sankarar ƙwayar cuta ta B cell (B-ALL).

Binciken, mai suna "Amfani Mai Tallafawa Mai Gudanar da Ƙaƙwalwar Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwararren Ƙwaƙwalwa na CAR-T yayi na iya daidaitawa da Kinetics na Kwayoyin CAR-T A cikin Vivo , yana nazarin yadda zaɓin mai gabatarwa zai iya rinjayar aikin CAR-T sel. Masu bincike Jin-Yuan Ho, Lin Wang, Ying Liu, Min Ba, Junfang Yang, Xian Zhang, Dandan Chen, Peihua Lu, da Jianqiang Li na Hebei Senlang Biotechnology da asibitin Lu Daopei ne suka jagoranci wannan bincike.

Sakamakon su ya nuna cewa yin amfani da MND (myeloproliferative sarcoma virus MPSV enhancer, korau iko yankin NCR shafewa, d1587rev primer daurin wurin maye gurbin) mai gabatarwa a cikin kwayoyin CAR-T yana haifar da ƙananan ƙananan ƙwayoyin CAR, wanda hakan ya rage yawan samar da cytokine. Wannan yana da mahimmanci saboda yana taimakawa wajen rage mummunar illar da ke hade da CAR-T far, irin su cytokine release syndrome (CRS) da CAR-T cell encephalopathy syndrome (CRES).

Gwajin asibiti, mai rijista a ƙarƙashin ClinicalTrials.gov mai gano NCT03840317, ya haɗa da marasa lafiya 14 zuwa ƙungiyoyi biyu: ɗayan yana karɓar ƙwayoyin CAR-T da MND ke jagoranta kuma ɗayan yana karɓar ƙwayoyin CAR-T masu tallata EF1A. Abin sha'awa, duk marasa lafiya da aka yi musu magani tare da ƙwayoyin CAR-T da MND ke tafiyar da su sun sami cikakkiyar gafara, tare da mafi yawansu suna nuna ƙarancin ƙarancin cuta-mara kyau bayan wata na farko. Har ila yau, binciken ya ba da rahoton ƙananan abubuwan da suka faru na CRS mai tsanani da CRES a cikin marasa lafiya da aka bi da su tare da MND-driven CAR-T sel idan aka kwatanta da waɗanda aka bi da su tare da ƙwayoyin EF1A.

Dokta Peihua Lu daga Asibitin Lu Daopei ya bayyana kyakkyawan fata game da yuwuwar wannan sabon tsarin, yana mai cewa, "Haɗin gwiwarmu da Hebei Senlang Biotechnology ya samar da mahimman bayanai game da inganta magungunan CAR-T. Ta hanyar daidaita mai talla, za mu iya inganta yanayin aminci. na jiyya yayin da ake ci gaba da yin tasiri.

Binciken ya samu tallafin ne daga gidauniyar kimiyyar dabi'a ta lardin Hebei da kuma sashen kimiya da fasaha na lardin Hebei. Yana nuna mahimmancin zaɓin mai gabatarwa a cikin haɓaka hanyoyin kwantar da hankali na CAR-T kuma yana buɗe sabbin hanyoyin magance cutar kansa mafi aminci da inganci.